The interesting story here is why Calico would license the molecule whereas traditional pharma was not as interested. Age related incurable conditions are the h

The interesting story here is why Calico would license the molecule whereas traditional pharma was not as interested. Age related incurable conditions are the happiest targets for blockbuster drugs. In all likelihood, someone with actual domain expertise would realize that there was already data which indicated the drug wouldn't make it to market. The team with the rights seized the moment of silicon valley longevity hype, and good for them.